|
2.6 Etiologie - Environnement
|
|
|
|
3. Prévention
|
|
|
Jane Wardle obituary [The Guardian]
|
|
|
|
|
|
Jane
Wardle, who has died aged 64 from cancer, was an outstanding
behavioural scientist in the field of cancer prevention. Alongside the
clinical gifts of empathy, listening and insight into human motives, she
had a rigorous, quantitative approach to research.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
FDA approves Lilly's lung cancer drug [Reuters]
|
|
|
|
|
|
A
1,093-patient clinical trial showed that patients who received
Portrazza, along with chemotherapy drugs gemcitabine and cisplatin,
survived an average of 11.5 months compared with 9.9 months for those
who received only chemotherapy treatments.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE consults on ovarian cancer treatments draft guidance [NICE]
|
|
|
|
|
|
The
draft guidance gives provisional recommendations on whether the drugs
paclitaxel, pegylated liposomal doxorubicin hydrochloride (PLDH),
topotecan, trabectedin and gemcitabine should be offered as treatment
options for ovarian cancer that has returned after prior chemotherapy
treatment.
|
|
|
|
|
|
|
Why Many Cancer Drugs Don't Have To Cost So Much [Forbes]
|
|
|
|
|
|
I’m
skeptical of, if not frankly opposed to, some proposed schemes for
assigning worth to cancer meds based on evidence of effectiveness.
First, because a lot of published evidence turns out to be wrong, or
inapplicable to individuals who might, really, benefit.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.9 Controverses
|
|
|